JAB-30355 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JAB-30355’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JAB-30355 overview
JAB-30355 (JAB-30300) is under development for the treatment of solid tumors, gastric cancer, ovarian cancer, breast cancer, pancreatic cancer and lung cancer. The drug candidate is administered through oral route and acts by targeting mutant p53 Y220C.
Jacobio Pharmaceuticals Group overview
Jacobio Pharmaceuticals Group (Jacobio Pharma) discovers and develops monotherapies to treat cancer. The company investigates JAB-3068 program for the treatment of solid tumors, esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); JAB-3312 drug against pancreatic cancer and KRAS mutation in colorectal cancer, osimertinib progressed and KRAS G12C mutation in NSCLC. It also evaluates JAB-8263 drug to treat solid tumors, myelofibrosis and acute myeloid leukemia (AML). Jacobio Pharma works in partnership with biotechnology and pharmaceutical companies. The company operates in Beijing and Shanghai, China and Massachusetts, the US. Jacobio Pharma is headquartered in Beijing, China.
For a complete picture of JAB-30355’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
